Clinical Trials Browser

Active not recruiting × aflutinib × 30 days × Clear all

NCT05364073 2026-03-13

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung